MedTrace Logo

Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases

NCT00928226 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-01-30

Study results available
· View outcomes & findings →

Summary

The maximum tolerated dose of 3-session (ie, treatment) stereotactic radiosurgery (SRS) to treat brain metastases greater than 4.2 cm³ in size will be determined.

This study investigates if increasing radiation dose improves outcome for patients without greater toxicity (side effects).

Conditions

  • Brain Cancer
  • Neoplasm Metastasis
  • Cancer of Brain and Nervous System
  • Metastatic Malignant Neoplasm to Brain

Interventions

RADIATION

Fractionated Stereotactic Radiosurgery (SRS)

Standard of care

PROCEDURE

Surgical resection

Standard of care

Sponsors & Collaborators

Principal Investigators

  • Clara Choi · Stanford University

  • Scott Soltys · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2017-10-31
Completion
2019-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00928226 on ClinicalTrials.gov